Explainable AI for breast cancer shows multidisciplinary logic ‘pixel by pixel’

Researchers in Europe have demonstrated an explainable AI technique for administering precision medicine to patients with breast cancer.

The advance represents the first cancer-care pathway offering an automatically combined analysis of morphological, molecular and histological data, according to a study published March 8 in Nature Machine Intelligence.

The team, led by a pathologist at Charité–Universitätsmedizin Berlin and a professor of machine learning at Technical University of Berlin, built their system to supply an easily readable visual aid—heatmaps—to show clinicians the AI’s “thinking” as well as its results.

“Pixel by pixel, these heatmaps show which visual information influenced the AI decision process and to what extent, thus enabling doctors to understand and assess the plausibility of the results of the AI analysis,” the institutions explain in a joint announcement. “This represents a decisive and essential step forward for the future regular use of AI systems in hospitals.”

The team’s next moves include clinically validating the approach in routine tumor diagnostics.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.